title: Dual antibody therapy to harness the innate anti-tumor immune response to enhance antibody targeting of tumors.
abstract: Cancer immunotherapy is a rapidly evolving field that offers a novel paradigm for cancer treatment: therapies focus on enhancing the immune system's innate and adaptive anti-tumor response. Early immunotherapeutics have achieved impressive clinical outcomes and monoclonal antibodies are now integral to therapeutic strategies in a variety of cancers. However, only recently have antibodies targeting innate immune cells entered clinical development. Innate immune effector cells play important roles in generating and maintaining antitumor immunity. Antibody-dependent cell-mediated cytotoxicity (ADCC) and antibody-dependent cellular phagocytosis (ADCP) are important innate immune mechanisms for tumor eradication. These cytolytic processes are initiated by the detection of a tumor-targeting antibody and can be augmented by activating co-stimulatory pathways or blocking inhibitory signals on innate immune cells. The combination of FDA-approved monoclonal antibodies with innate effector-targeting antibodies has demonstrated potent preclinical therapeutic synergy and early-phase combinatorial clinical trials are ongoing.
authors.affiliation: Department of Medicine, Division of Oncology, Stanford University, Stanford, CA 94305, USA.
authors.forename: Cariad
authors.initials: C
authors.lastname: Chester
authors.affiliation: Institute de Gustave Roussy Service, Paris, France.
authors.forename: Aurelien
authors.initials: A
authors.lastname: Marabelle
authors.affiliation: Service d'Hématologie Clinique, Centre Hospitalier Universitaire de Rennes, Rennes, France; CHU Rennes, Service Hématologie Clinique, F-35033 Rennes, France; INSERM, U917, F-35043 Rennes, France.
authors.forename: Roch
authors.initials: R
authors.lastname: Houot
authors.affiliation: Department of Medicine, Division of Oncology, Stanford University, Stanford, CA 94305, USA. Electronic address: Kohrt@stanford.edu.
authors.forename: Holbrook E
authors.initials: HE
authors.lastname: Kohrt
mesh_terms: D000818:Animals; D000911:Antibodies, Monoclonal / Q000494:pharmacology* / Q000627:therapeutic use*; D000920:Antibody-Dependent Cell Cytotoxicity; D000970:Antineoplastic Agents / Q000494:pharmacology / Q000627:therapeutic use; D002986:Clinical Trials as Topic; D006801:Humans; D007113:Immunity, Innate / Q000187:drug effects*; D007167:Immunotherapy; D058990:Molecular Targeted Therapy; D009369:Neoplasms / Q000276:immunology* / Q000378:metabolism / Q000628:therapy*; D016896:Treatment Outcome
chemical_list: D000911:Antibodies, Monoclonal; D000970:Antineoplastic Agents